인사이트
Insights From Our Experts
Articles
Ensuring Speed, Scale and Certainty in Supply Chain
Every twist and turn in the bench-to-bedside commercialization journey introduces increasing regulatory complexity, product-specific special handling requirements, and evolving industry guidelines. With more than 300 client case studies to draw from, we’ve found three opportunities (or…
Breaking the Cycle of Supply Chain Complexity
As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can…
Managing Risks to Improve Health Outcomes: How to Move Population Health Forward in an Era of Uncertainty
At the Canadian Association for Population Therapeutics (CAPT) Annual Conference, Sumeet Singh, Senior Director, EVERSANA, delivered a presentation on pharmacoeconomic analysis and outcome-based agreements and what they mean for Canadian private payers. Watch his session below…
The Power of Working Together With the Rare Disease Community
Posted by
Seth Gordon on 11월 6, 202011/6/20
“Alone, we can do so little; together, we can do so much.” – Helen Keller This sentiment addresses the power of working together to improve health in rare disease. At EVERSANA, we have developed a unique…
Do Germany’s New Hemophilia Regulations Have Wider-Reaching Implications?
In July 2019, the Drug Safety and Supply Law (GSAV) was passed by Germany’s Higher Chamber of Parliament, bringing about substantial changes to Germany’s health policy. Besides introducing new strategies for biosimilar uptake and cell and…
Four Ways Predictive Analytics Can Strengthen Your Commercialization Efforts
Over the past few years, artificial intelligence (AI) and machine learning (ML) have been trending topics in healthcare but are now being propelled to the forefront of clinical decision support and care delivery. Some organizations, however,…
Optimizing the Performance of a PSP and Improving Outcomes For All Stakeholders
Patient Support Programs (PSP) have been proven to improve clinical and patient outcomes and help manage patient out-of-pocket cost and prescribed use. Particularly for specialty drugs, the services provided under the PSP umbrella not only help…
ODRD Insights: Building an AI-Driven Data Ecosystem to Drive Commercial Activities
The market landscape, especially for rare diseases, is dynamic and presents a unique set of challenges for the life sciences industry. Unlike the case for broader disease states, most rare disease patients are not correctly diagnosed…
The U.S. Pharma Market Outlook: Path to Recovery and the New Normal
With the U.S. presidential election days away and the continued impact of a pandemic, EVERSANA and Reuters gathered industry leaders to discuss what is to come. Watch as the panel discusses the tough questions facing pharma,…
NORD 2020 Insights: Entering a New Era
EVERSANA was a proud sponsor of the 2020 NORD Rare Diseases & Orphan Products Breakthrough Summit to advance the dialogue on ways to improve the lives of over 25 million Americans living with rare diseases. Our…